Amneal Pharmaceuticals Submits Biosimilar XOLAIR® (Omalizumab) BLA to FDA, Marking Key Step Toward U.S. Regulatory Approval
Reuters
Sep 26
Amneal Pharmaceuticals Submits Biosimilar XOLAIR® (Omalizumab) BLA to FDA, Marking Key Step Toward U.S. Regulatory Approval
Amneal Pharmaceuticals Inc. has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a proposed biosimilar to XOLAIR® (omalizumab), developed in partnership with Kashiv BioSciences, LLC. This marks a significant step toward potential regulatory approval, positioning Amneal for first-wave entry into the $4 billion U.S. omalizumab market. The product is intended to treat conditions such as moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic spontaneous urticaria. Amneal holds exclusive U.S. commercialization rights, pending FDA approval. No external grant or funding was reported in connection with this regulatory submission; the milestone reflects ongoing collaboration between Amneal and Kashiv BioSciences.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9535723-en) on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.